Diagnostic platform for early detection of liver disease
Luminist developed a non-invasive diagnostic test for the early detection and staging of liver fibrosis and non-alcoholic steatohepatitis (NASH). Luminist was acquired in 2020 by DiscernDx.
What they do:
Cofactor closes the precision medicine gap with predictive diagnostics
Quick facts:
HQ: St. Louis, MO, United States
What they do:
The genetic testing platform detecting and measuring disease.
Quick facts:
HQ: San Francisco, CA, United States
What they do:
Engineering a future without cancer deaths.
Quick facts:
HQ: San Francisco, CA, United States
What they do:
Patient Intelligence Platform for Genetic Disease
Quick facts:
HQ: San Francisco, CA, United States
What they do:
First ECG AI to go beyond diagnostics and recommend treatment
Quick facts:
HQ: San Francisco, CA, United States
What they do:
We make injections as easy as pushing a button!
Quick facts:
HQ: Boston, MA, United States
Diagnostic platform for early detection of liver disease
New York, NY, United States
2 employees, according to the company profile.
There are no funding rounds for Luminist Labs in our data.
Similar startups: Cofactor Genomics, BillionToOne, and Numen.